Quest Diagnostics DGX is set to release its second-quarter 2025 results on July 22, before the market opens. The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.21 in the ...

Michael Cherny, an analyst from Leerink Partners, maintained the Hold rating on Quest Diagnostics (DGX – Research Report). The associated price target is $169.00. Don't Miss our Black Friday Offers: ...

DUBLIN--(BUSINESS WIRE)--The "Next Generation Technologies Enabling High Performance Diagnostic Device" report has been added to ResearchAndMarkets.com's offering. Technology Convergence Driving ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced its AI-driven molecular ...

Valued at a market cap of $17.1 billion, Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic testing and services in the United States and internationally. Based in Secaucus, New ...

On Tuesday, Quest Diagnostics Inc (NYSE:DGX) posted second-quarter adjusted EPS of $2.35, beating the consensus of $2.34. Sales increased 2.5% year-over-year to $2.39 billion, almost in line with the ...

Assessing the skills of junior female footballers in realistic game situations: this is now possible with the new SCoRE performance diagnostics system developed by the University of Würzburg. The ...